Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
22 hedge funds and large institutions have $4.81M invested in Bellerophon Therapeutics, Inc. in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 6 closing their positions.
19% less funds holding
Funds holding: 27 → 22 (-5)
24% less capital invested
Capital invested by funds: $6.34M → $4.81M (-$1.53M)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.7K |
| 2 |
BlackRock
New York
|
+$17.2K |
| 3 |
Rockefeller Capital Management
New York
|
+$4.17K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$2.08K |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$231K |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$99K |
| 3 |
VF
Virtu Financial
New York
|
-$80K |
| 4 |
E
Ergoteles
New York
|
-$67K |
| 5 |
Millennium Management
New York
|
-$59K |
BLPH Hedge Fund Activity: Q3 2021 in Review
22 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2021, worth a combined $4.81M — down 24% from $6.34M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BLPH and 1 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $18.7K. The largest seller was Renaissance Technologies, cutting an estimated $231K.
- 22 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2021, down from 27 in Q2 2021.
- Funds reported $4.81M of Bellerophon Therapeutics, Inc. stock for Q3 2021, down 24% quarter-over-quarter.
- 1 fund opened new Bellerophon Therapeutics, Inc. positions in Q3 2021 and 6 closed out, a net change of -5 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q3 2021 was Vanguard Group, an estimated $18.7K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q3 2021 was Renaissance Technologies, an estimated $231K sold.
Based on aggregated 13F filings for Q3 2021.